Syneron Announces the Global Launch of the eTwo™, a new Combination of Advanced Technologies for Facial Treatments

YOKNEAM, Israel, October 20, 2011 /PRNewswire/ --

eTwo combines the unique Sublime™ and Sublative™ applications for comprehensive facial rejuvenation

Syneron Medical Ltd. (NASDAQ: ELOS), http://www.syneron.com, the global leader in medical aesthetic products and technology, announced today the global launch of the new eTwo device, a combination of advanced technologies for facial treatments, to be showcased in the upcoming EADV 2011 - European Academy of Dermatology and Venereology - Lisbon, Portugal.

The eTwo is FDA cleared and CE marked for dermatological procedures requiring ablation, resurfacing and wrinkle treatment.

"We are extremely pleased to offer technological improvements in a market that demands safe and effective solutions. eTwo's unique combination of Sublime™ controlled heating and Sublative™ fractional skin treatment allows doctors and patients to see dramatic results in skin texture and laxity both immediately and over time as the rejuvenation process can continue for several weeks after the procedure," said Louis Scafuri, CEO of Syneron.

More specifically, Sublime™ uses the elos™ combination of safe and effective levels of infrared light and bi-polar radio frequency energies to remodel the deep dermal layer of the skin by stimulating new collagen growth. At the same time, Syneron's revolutionary Sublative™ fractionated bi-polar radio frequency technology places heat energy in the upper layers of the dermis allowing for a significant increase in collagen and elastin production for a brighter and smoother complexion. This Sublative breakthrough technology offers a high dermal impact with low epidermal disruption. Together, these two applications are taking skin rejuvenation treatments a step further.

The eTwo system supports the new Sublative iD tips, intelligently designed tips to maximize treatment options and results.

"I have consistently experienced impressive results when treating patients with dyschromia and mild to moderate skin laxity," says Brian Biesman, M.D, F.A.C.S., Vanderbilt University Medical Center Nashville, TN, who is part of the on-going eTwo study.

According to Dr. Shimon Eckhouse, Chairman of the Board of Syneron, "Our new eTwo device is in line with our research and development based strategy that aims to reach beyond existing technologies in order to provide our customers and their patients with solutions that will better meet their needs and expectations."

For more information about eTwo visit http://www.syneron.com.

About Syneron Medical Ltd.

Syneron Medical Ltd. - is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

About eTwo™

eTwo™ is a comprehensive facial rejuvenation device sold to professionals only. All information provided is intended for informational purposes only. The information about skin conditions provided herein does not constitute medical or pharmaceutical advice and should not be relied upon as a substitute for qualified medical consultation with health professionals.

Contacts:
Linda.Pavy@bm.com - Burson-Marsteller Agency
+ 33-1 41-86-76-26

Syneron PR - pr@syneron.com

Asaf Alperovitz - Syneron Chief Financial Officer
+ 972-73-244-2283